Overview
Emi Gal is co-founder and chief executive officer of Ezra, whose mission is to detect cancer early for everyone in the world per ezra.com/mission. Gal is a software engineer and entrepreneur with a 15-year track record building successful technology companies and bringing them to a worldwide stage. Prior to Ezra, he launched Brainient, an advertising technology company acquired by Teads; he helped scale Teads to $1B in annual revenue as CEO of Teads Studio.
Ezra believes checking your body for cancer should be the easiest part of your health routine. Early cancer detection increases survival rates to over 80% per Ezra’s mission page — framing MRI screening as proactive health infrastructure.
Role and company
As Co-Founder and CEO, Gal leads Ezra’s MRI and low-dose CT scanning protocols designed with top medical experts to help identify potential cancer in up to 13 organs per mission page materials. Ezra provides AI-enhanced MRI screening across U.S. outpatient imaging partnerships and membership pricing models.
Gal’s leadership team includes Chief Scientist Dan Sodickson — inventor of parallel imaging in MRI and Chief of Innovation at NYU Grossman School of Medicine — and Chief Medical Officer Danna Chung, MD, triple board-certified per mission page roster.
Background and career context
Gal’s prior Brainient founding and Teads Studio CEO role — scaling to $1B annual revenue after acquisition — gave him ad-tech growth experience applied to consumer health services at Ezra. Ezra mission page establishes Gal as software engineer and serial entrepreneur without listing formal medical training on the cited biography.
Gal’s consumer go-to-market approach contrasts with hospital-centric clinical AI vendors — targeting individuals willing to pay for screening outside traditional insurance preventive schedules.
Company-building or leadership context
Gal founded Ezra in 2018 in New York per company press materials, building AI that enhances MRI acquisition and reporting to reduce scan time and cost. June 1, 2023 FDA 510(k) clearance for AI enhancing MRI enabled fast, low-cost scans per Ezra press releases on mission page news section. February 2024 Ezra raised $21 million to increase access to care per press materials.
Ezra’s scientific advisor roster spans NYU, Memorial Sloan Kettering, RadNet, and Columbia — giving Gal clinical protocol credibility for consumer-facing screening claims.
Public milestones
2018: Ezra founded by Emi Gal. June 1, 2023: FDA 510(k) clearance for AI enhancing MRI. February 8, 2024: Ezra raised $21M per press release on mission page. Ezra operates across dozens of U.S. locations per company news materials. October 2024: Ezra and Bryan Johnson launched advanced longevity scan per press coverage listed on mission page.
Gal is Co-Founder and CEO on ezra.com/mission reviewed July 10, 2026.
Why their work matters
Ezra under Gal tests whether full-body MRI screening can become consumer health routine when AI reduces cost and time barriers — a controversial but fast-growing category payers and physicians debate. Gal’s ad-tech scaling background brings growth marketing discipline uncommon among physician-founded diagnostics companies.
For healthcare AI readers, Ezra is consumer diagnostic AI — distinct from hospital radiology AI but pushing MRI workflow innovation through outpatient partnerships like RadNet.
Sources and references
Primary sourcing: Ezra Mission leadership page, reviewed July 10, 2026.
- Ezra — Mission (ezra.com)
Brainient, Teads, and funding milestones from Ezra mission page and listed press releases only.
Ezra mission page states over 30 scientific advisors from NYU, Memorial Sloan Kettering, RadNet, and Columbia design scanning protocols detecting potential cancer in up to 13 organs — clinical governance Gal maintains as non-physician founder CEO. June 2023 FDA 510(k) clearance for AI-enhanced MRI and February 2024 $21M raise per mission page press releases give Gal regulatory and capital milestones for consumer screening expansion.